Summary The Asia-Pacific region is home to more than half of the global population and
accounted for 62· 6% of global deaths due to liver diseases in 2015. 54· 3% of global deaths …

This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016
Practice Guidelines for Treatment of Chronic Hepatitis B (1) and update the previous …

Under the terms of this licence, you may copy, redistribute and adapt the work for
noncommercial purposes, provided the work is appropriately cited, as indicated below. In …

Hepatitis B virus (HBV) infection remains a global public health problem with changing
epidemiology due to several factors including vaccination policies and migration. This …

We present here the first update of the 2013 EFSUMB (European Federation of Societies for
Ultrasound in Medicine and Biology) Guidelines and Recommendations on the clinical use …

Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs
categorized into 13 functional groups have been formally approved for the treatment of the …

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest
rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection …

Background In 2016, of the estimated 257 million people living with chronic hepatitis B virus
(HBV) infection worldwide, only a small proportion was diagnosed and treated. The …

Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …

Hepatitis B reactivation associated with immune-suppressive and biological therapies is
emerging to be an important cause of morbidity and mortality in patients with current or prior …